Look Under The Hood: FXH Has 16% Upside
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 15 2024
0mins
Source: NASDAQ.COM
- Analyst Target Prices for ETFs: Analysts have calculated the implied target price for the First Trust Health Care AlphaDEX Fund ETF (FXH) to be $123.87 per unit, indicating a 15.67% upside from its current trading price of $107.09 per unit.
- Stock Analysis and Investor Considerations: The article discusses the analyst target prices for specific holdings within FXH, such as Sarepta Therapeutics Inc, Envista Holdings Corp, and Zoetis Inc, highlighting potential upsides and the importance of investor research in evaluating these targets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 78.710
Low
130.00
Averages
154.20
High
200.00
Current: 78.710
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Zoetis Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply to be lead plaintiff by July 27, 2026, without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Zoetis made false or misleading statements during this period, failing to disclose declining market shares for key products, particularly canine medications like Librela and Simparica Trio, leading to investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its successful track record and extensive experience in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven leadership experience to ensure effective representation in the class action.
See More
Reminder for Zoetis Investors on Class Action Lawsuit
- Lawsuit Background: Zoetis reported weakened demand in its Companion Animal portfolio in Q2 and Q3 2025, resulting in stock price declines of 3.8% and 13.8%, causing significant investor losses.
- Deteriorating Financial Performance: The Q1 2026 report indicated slowing overall revenue growth and declining Companion Animal sales, leading to a 21.5% drop in stock price to $87.31, further exacerbating investor losses.
- Increased Market Competition: The company acknowledged heightened price sensitivity and competitive pressures in pet care, particularly in dermatology and parasiticides, resulting in market share loss and reduced prescription volumes.
- False Statement Allegations: The class action lawsuit alleges that the company failed to disclose critical negative information throughout the class period, including weakening veterinarian prescription growth and market share losses, misleading investors significantly.
See More
Zoetis Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman has initiated a class action lawsuit against Zoetis Inc., seeking damages for investors who purchased securities between January 14, 2025, and May 6, 2026, highlighting significant investor concerns regarding potential violations of federal securities laws.
- Allegations of Misrepresentation: The complaint alleges that Zoetis made materially false and misleading statements regarding the growth and veterinarian adoption of key products, failing to disclose that the prescription growth of Librela was sharply weakening due to FDA safety warnings, which could undermine investor confidence in the company's future.
- Market Share Loss: Zoetis' Simparica Trio is reportedly losing significant market share to a lower-priced competing product, which poses a threat to its financial performance, especially in a slowing overall market, indicating potential challenges ahead for the company's revenue streams.
- Investor Action Deadline: Affected investors have until July 27, 2026, to request appointment as lead plaintiff, suggesting that the ongoing legal risks could negatively impact the company's stock price, necessitating close monitoring of developments by investors.
See More
Zoetis Faces Class Action Lawsuit Reminder for Securities Violations
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Zoetis for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 14, 2025, and May 6, 2026, with a deadline to contact the firm by July 27, 2026.
- Market Misrepresentation: The complaint alleges that Zoetis made false and misleading statements during the class period, primarily due to weakened veterinarian prescription growth for its Librela medication following FDA safety warnings, resulting in investor losses.
- Declining Market Share: Zoetis's Trio product lost market share to competitors, while its Apoquel and Cytopoint dermatology products faced challenges from newly launched competing treatments, exacerbating the company's market pressures.
- Investor Losses: As the market became aware of the truth regarding Zoetis, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit for recovery, highlighting significant deficiencies in the company's transparency and compliance.
See More
Zoetis Faces Class Action Lawsuit as Shares Plunge 21.5%
- Stock Price Plunge: Zoetis shares fell by $23.91, a 21.5% drop, on May 7, 2026, after the company admitted intensified competition in core pet care categories, severely undermining investor confidence and potentially impacting future financing capabilities.
- Lawsuit Background: A class action lawsuit has been filed on behalf of shareholders who purchased Zoetis securities between January 14, 2025, and May 6, 2026, alleging that the company concealed declining market share amidst increasing competition, which could lead to significant financial losses for investors.
- Market Share Erosion: Zoetis's products like Librela and Simparica Trio are facing strong challenges from competitors such as Elanco, threatening its dominance in the pet care market and exacerbating investor concerns about the company's future performance.
- Disclosure Obligations: The lawsuit highlights the importance of competitive disclosure in the animal health sector, suggesting that Zoetis's management's underestimation of competitive risks over the past year may have led to a decline in shareholder confidence regarding the company's future prospects.
See More
Investment Opportunities in the Healthcare Sector
- Healthcare Spending Growth: U.S. healthcare spending is projected to reach nearly $5.3 trillion in 2024, indicating long-term growth potential in the sector, making stocks like CRISPR, Zoetis, and Danaher attractive for investors.
- CRISPR's Innovation Potential: CRISPR Therapeutics leads in gene editing, with its FDA-approved Casgevy treatment expected to boost sales from $36 million to $145 million, presenting a volatile yet promising long-term investment opportunity.
- Zoetis Market Rebound: Despite negative publicity from Librela, Zoetis trades at a low P/E of 11 compared to its historical average of 37, with analysts forecasting a 9% annual growth over the next three years, offering a compelling investment case.
- Danaher's Acquisition Strategy: Danaher recently acquired Masimo for $9.9 billion, enhancing its position in pulse oximetry technology; despite a 40% drop from its peak, the stock's future growth potential remains strong and appealing to investors.
See More
Reminder of Zoetis Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply to be lead plaintiff by July 27, 2026, without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Zoetis made false or misleading statements during this period, failing to disclose declining market shares for key products, particularly canine medications like Librela and Simparica Trio, leading to investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its successful track record and extensive experience in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven leadership experience to ensure effective representation in the class action.
See More
Reminder for Zoetis Investors on Class Action Lawsuit
- Lawsuit Background: Zoetis reported weakened demand in its Companion Animal portfolio in Q2 and Q3 2025, resulting in stock price declines of 3.8% and 13.8%, causing significant investor losses.
- Deteriorating Financial Performance: The Q1 2026 report indicated slowing overall revenue growth and declining Companion Animal sales, leading to a 21.5% drop in stock price to $87.31, further exacerbating investor losses.
- Increased Market Competition: The company acknowledged heightened price sensitivity and competitive pressures in pet care, particularly in dermatology and parasiticides, resulting in market share loss and reduced prescription volumes.
- False Statement Allegations: The class action lawsuit alleges that the company failed to disclose critical negative information throughout the class period, including weakening veterinarian prescription growth and market share losses, misleading investors significantly.
See More
Zoetis Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman has initiated a class action lawsuit against Zoetis Inc., seeking damages for investors who purchased securities between January 14, 2025, and May 6, 2026, highlighting significant investor concerns regarding potential violations of federal securities laws.
- Allegations of Misrepresentation: The complaint alleges that Zoetis made materially false and misleading statements regarding the growth and veterinarian adoption of key products, failing to disclose that the prescription growth of Librela was sharply weakening due to FDA safety warnings, which could undermine investor confidence in the company's future.
- Market Share Loss: Zoetis' Simparica Trio is reportedly losing significant market share to a lower-priced competing product, which poses a threat to its financial performance, especially in a slowing overall market, indicating potential challenges ahead for the company's revenue streams.
- Investor Action Deadline: Affected investors have until July 27, 2026, to request appointment as lead plaintiff, suggesting that the ongoing legal risks could negatively impact the company's stock price, necessitating close monitoring of developments by investors.
See More
Zoetis Faces Class Action Lawsuit Reminder for Securities Violations
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Zoetis for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 14, 2025, and May 6, 2026, with a deadline to contact the firm by July 27, 2026.
- Market Misrepresentation: The complaint alleges that Zoetis made false and misleading statements during the class period, primarily due to weakened veterinarian prescription growth for its Librela medication following FDA safety warnings, resulting in investor losses.
- Declining Market Share: Zoetis's Trio product lost market share to competitors, while its Apoquel and Cytopoint dermatology products faced challenges from newly launched competing treatments, exacerbating the company's market pressures.
- Investor Losses: As the market became aware of the truth regarding Zoetis, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit for recovery, highlighting significant deficiencies in the company's transparency and compliance.
See More
Zoetis Faces Class Action Lawsuit as Shares Plunge 21.5%
- Stock Price Plunge: Zoetis shares fell by $23.91, a 21.5% drop, on May 7, 2026, after the company admitted intensified competition in core pet care categories, severely undermining investor confidence and potentially impacting future financing capabilities.
- Lawsuit Background: A class action lawsuit has been filed on behalf of shareholders who purchased Zoetis securities between January 14, 2025, and May 6, 2026, alleging that the company concealed declining market share amidst increasing competition, which could lead to significant financial losses for investors.
- Market Share Erosion: Zoetis's products like Librela and Simparica Trio are facing strong challenges from competitors such as Elanco, threatening its dominance in the pet care market and exacerbating investor concerns about the company's future performance.
- Disclosure Obligations: The lawsuit highlights the importance of competitive disclosure in the animal health sector, suggesting that Zoetis's management's underestimation of competitive risks over the past year may have led to a decline in shareholder confidence regarding the company's future prospects.
See More
Investment Opportunities in the Healthcare Sector
- Healthcare Spending Growth: U.S. healthcare spending is projected to reach nearly $5.3 trillion in 2024, indicating long-term growth potential in the sector, making stocks like CRISPR, Zoetis, and Danaher attractive for investors.
- CRISPR's Innovation Potential: CRISPR Therapeutics leads in gene editing, with its FDA-approved Casgevy treatment expected to boost sales from $36 million to $145 million, presenting a volatile yet promising long-term investment opportunity.
- Zoetis Market Rebound: Despite negative publicity from Librela, Zoetis trades at a low P/E of 11 compared to its historical average of 37, with analysts forecasting a 9% annual growth over the next three years, offering a compelling investment case.
- Danaher's Acquisition Strategy: Danaher recently acquired Masimo for $9.9 billion, enhancing its position in pulse oximetry technology; despite a 40% drop from its peak, the stock's future growth potential remains strong and appealing to investors.
See More
